Clinical trials: psoriasis
Psoriasis
A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis
The objectives of this study are to compare the efficacy and safety of DFD01 Spray to Vehicle Spray for topical treatment of moderate plaque psoriasis
- Trial name
- NCT01967069
- Testing
- DFD01 Spray, Vehicle Spray
- Where
- 28 sites in United States
- Volunteers
- 277 people
- Sponsor
- Primus Pharmaceuticals
Psoriasis Vulgaris
Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy
This study was performed to evaluate the safety, tolerability, activity, pharmacokinetics (PK), and daily dose regimen of KD025 administered orally (PO) for 12 weeks to subjects with psoriasis vulgaris who failed at least one…
- Trial name
- NCT02317627
- Testing
- KD025
- Where
- 9 sites in United States
- Volunteers
- 38 people
- Sponsor
- Kadmon Corporation, LLC
Psoriasis
A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
This is a Phase IV open-label study to evaluate the efficacy and safety of SC efalizumab in adult subjects (18 years of age and older) with chronic moderate or worse plaque psoriasis who have had an inadequate response to…
- Trial name
- NCT00336973
- Testing
- efalizumab
- Volunteers
- 73 people
- Sponsor
- Genentech, Inc.
Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
The purpose of this study is to evaluate the safety and efficacy of 4 weeks of TACLONEX ointment in adolescent patients with psoriasis vulgaris.
- Trial name
- NCT00817219
- Testing
- Calcipotriene plus betamethasone dipropionate ointment
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- LEO Pharma
Spondyloarthritis
99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis
This single center, open-label, proof of concept (PoC) Phase II study aimed to assess the investigational imaging agent 99mTc-rhAnnexin V-128 in detecting spondyloarthritis (SpA) lesions.
- Trial name
- Annexin 03 (NCT03232580)
- Testing
- rhAnnexin V-128
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Advanced Accelerator Applications
Psoriasis
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy of guselkumab compared with secukinumab for the treatment of participants with moderate to severe plaque-type psoriasis.
- Trial name
- ECLIPSE (NCT03090100)
- Testing
- Guselkumab, Secukinumab
- Where
- 142 sites in United States, Australia and 7 more
- Volunteers
- 1,048 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis
The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00307437
- Testing
- Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
- Where
- 62 sites in United States, Austria and 5 more
- Volunteers
- 1,230 people
- Sponsor
- Centocor Research & Development, Inc.
Rheumatoid Arthritis, Plaque Psoriasis
A Long Term Safety Extension Study (CHS-0214-05)
An Open-label, Safety Extension Study (OLSES) evaluating the longer-term safety and durability of response of subjects who completed 48 weeks of evaluations in the confirmatory safety and efficacy studies, CHS 0214-02 or…
- Trial name
- NCT02486939
- Testing
- CHS-0214
- Where
- Japan
- Volunteers
- 359 people
- Sponsor
- Coherus Oncology, Inc.
Psoriasis Vulgaris, Plaque Psoriasis
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
The aim of this study is to evaluate safety, tolerability, and efficacy of PRCL-02 in moderate to severe chronic plaque psoriasis
- Trial name
- NCT03614078
- Testing
- PRCL-02
- Where
- 16 sites in Canada, Slovakia and 1 more
- Volunteers
- 92 people
- Sponsor
- PRCL Research Inc.
Psoriatic Arthritis
REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)
The overall objective of the study was to describe the long-term effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting.
- Trial name
- NCT00127842
- Testing
- Etanercept
- Volunteers
- 110 people
- Sponsor
- Amgen
Psoriasis
Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
The primary hypothesis of this trial is that the addition of short courses of clobetasol propionate foam to etanercept monotherapy in subjects with moderate to severe plaque psoriasis will yield greater efficacy compared with…
- Trial name
- NCT01235442
- Testing
- 1=Etanercept, 2=Clobetasol propionate foam
- Volunteers
- 592 people
- Sponsor
- Amgen
Psoriasis
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
The objective of this Phase 2 trial is to determine the efficacy and safety of LYC-30937-EC in patients with moderate plaque-type psoriasis.
- Trial name
- NCT02872285
- Testing
- Drug: LYC-30937-EC
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- Lycera Corp.
Rheumatoid Arthritis, Psoriasis
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth in healthy patients and patients with average to very serious Psoriasis (a condition characterized by itchy, dry skin with a scaly…
- Conditions
- Rheumatoid Arthritis, Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Diseases
- Trial name
- NCT03329885
- Testing
- BMS-986251
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Psoriasis
The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment
This study aims to see if patient quality of life can be approved after treatment with an injectable medication called ustekinumab for the treatment of generalized psoriasis.
- Trial name
- NCT01511315
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Psoriasis
Immunologic Response to Secukinumab in Plaque Psoriasis
This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions.
- Trial name
- NCT02592018
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Generalized Pustular Psoriasis, Erythrodermic Psoriasis
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279.
- Trial name
- NCT06323356
- Testing
- TAK-279
- Where
- 20 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Takeda
Psoriasis Guttate, Plaque Psoriasis
Guselkumab Immunogenetics
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
- Trial name
- TIG (NCT04645355)
- Testing
- Guselkumab
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Psoriasis
Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab
Primary objective To evaluate the quality of life of Adalimumab treated patients over a period of 12 months Secondary objectives To evaluate the long-term efficacy of Adalimumab in patients with moderate to severe chronic plaque…
- Trial name
- NCT01077128
- Where
- 61 sites in Greece
- Volunteers
- 500 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)
This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis.
- Trial name
- NCT04535999
- Testing
- Secukinumab Auto-Injector
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pennsylvania
Psoriasis
Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis
The purpose of this study is to evaluate the use of etanercept (Enbrel®) in the treatment of psoriasis in patients for a period of up to 1 year.
- Trial name
- NCT00332332
- Testing
- etanercept
- Volunteers
- 246 people
- Sponsor
- Amgen